TY - JOUR
T1 - Comparing Different As-Treated Approaches
T2 - A Methodological Study Using Real-World Data on Psoriasis Treatments
AU - Kim, Sejun
AU - Jensen, Andreas
AU - Egeberg, Alexander
AU - Stensballe, Lone Graff
N1 - © 2026 The Author(s). Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd.
PY - 2026/2
Y1 - 2026/2
N2 - BACKGROUND: Accurate pharmaco-epidemiological assessment of the safety of biological treatments is essential but methodologically challenging.AIMS: This study evaluated how different assumptions regarding treatment switching and treatment episode definitions affect outcome estimates in psoriasis patients, focusing on malignancies and serious infections.METHODS: Data from Danish national registers (2009-2022) were analyzed for hospitalized psoriasis patients treated with ustekinumab, non-biologics, tumor necrosis factor-α inhibitors, and other interleukin inhibitors excluding ustekinumab. Various as-treated approaches were assessed and compared to the Intention-to-Treat (ITT) approach. The as-treated approaches included: (1) RC-switch, considering switching only between ustekinumab and the comparator in question, (2) Bio-switch, considering switches among all biologics, (3) Multi-switch, analyzing all groups simultaneously, and (4) Hierarchy-switch, analyzing switching by a predefined hierarchy. Hazard ratios (HRs) and 95% confidence intervals (CIs) were analyzed using Cox models. Sensitivity analyses incorporated treatment episodes based on the defined daily dose (DDD) and grace periods.RESULTS: Broader treatment switching allowances affected outcome estimates. For malignancies, the Bio-switch approach yielded the largest HR changes relative to the ITT. For serious infections, also, Bio-switch produced the largest HR shifts, for example, HR 1.32 (CI 1.09, 1.58) versus ITT HR 1.08 (CI 0.91, 1.29). Sensitivity analyses showed that accounting for episode gaps influenced HRs and widened CIs.CONCLUSION: The number of events within the exposure group varied by approaches, influencing the HR estimates. The multi-switch approach effectively captured treatment switching and reduced statistical uncertainty, supporting clearer safety conclusions. Tracking each treatment period with gaps reflects real-world practice but may lower statistical power and should be carefully considered in analyses.
AB - BACKGROUND: Accurate pharmaco-epidemiological assessment of the safety of biological treatments is essential but methodologically challenging.AIMS: This study evaluated how different assumptions regarding treatment switching and treatment episode definitions affect outcome estimates in psoriasis patients, focusing on malignancies and serious infections.METHODS: Data from Danish national registers (2009-2022) were analyzed for hospitalized psoriasis patients treated with ustekinumab, non-biologics, tumor necrosis factor-α inhibitors, and other interleukin inhibitors excluding ustekinumab. Various as-treated approaches were assessed and compared to the Intention-to-Treat (ITT) approach. The as-treated approaches included: (1) RC-switch, considering switching only between ustekinumab and the comparator in question, (2) Bio-switch, considering switches among all biologics, (3) Multi-switch, analyzing all groups simultaneously, and (4) Hierarchy-switch, analyzing switching by a predefined hierarchy. Hazard ratios (HRs) and 95% confidence intervals (CIs) were analyzed using Cox models. Sensitivity analyses incorporated treatment episodes based on the defined daily dose (DDD) and grace periods.RESULTS: Broader treatment switching allowances affected outcome estimates. For malignancies, the Bio-switch approach yielded the largest HR changes relative to the ITT. For serious infections, also, Bio-switch produced the largest HR shifts, for example, HR 1.32 (CI 1.09, 1.58) versus ITT HR 1.08 (CI 0.91, 1.29). Sensitivity analyses showed that accounting for episode gaps influenced HRs and widened CIs.CONCLUSION: The number of events within the exposure group varied by approaches, influencing the HR estimates. The multi-switch approach effectively captured treatment switching and reduced statistical uncertainty, supporting clearer safety conclusions. Tracking each treatment period with gaps reflects real-world practice but may lower statistical power and should be carefully considered in analyses.
KW - Humans
KW - Psoriasis/drug therapy
KW - Denmark/epidemiology
KW - Registries/statistics & numerical data
KW - Female
KW - Male
KW - Ustekinumab/adverse effects
KW - Middle Aged
KW - Biological Products/adverse effects
KW - Drug Substitution/statistics & numerical data
KW - Adult
KW - Neoplasms/epidemiology
KW - Aged
KW - Intention to Treat Analysis
KW - Dermatologic Agents/adverse effects
KW - Pharmacoepidemiology
KW - Proportional Hazards Models
UR - https://www.scopus.com/pages/publications/105028980304
U2 - 10.1002/pds.70337
DO - 10.1002/pds.70337
M3 - Journal article
C2 - 41609057
SN - 1053-8569
VL - 35
SP - e70337
JO - Pharmacoepidemiology and Drug Safety
JF - Pharmacoepidemiology and Drug Safety
IS - 2
M1 - e70337
ER -